Elenae Therapeutics Analysis
What is Elenae Therapeutics?
Elenae Therapeutics develops AI-designed antisense oligonucleotide therapies targeting heart, skeletal muscle, retina, and lung tissues. The platform uses LNA mixmer ASOs with phosphorothioate backbones for tissue penetration. Early data shows strong efficacy and safety in mice, pigs, and non-human primates across multiple aging-related and rare diseases.
Location
Berkeley, United States
Employees
1-10
Founded
2021
Product Features & Capabilities
- AI-designed antisense oligonucleotides targeting heart, skeletal muscle, retina, and lung
- LNA mixmer ASOs with phosphorothioate backbone
- Subcutaneous delivery once-weekly to once-monthly
- Efficacy and safety data in mice, pigs, and non-human primates
Use Cases
Target microRNAs in heart failure; Treat dry age-related macular degeneration; Address aging-related sarcopenia; Manage Duchenne and Becker muscular dystrophies; Deliver ASOs to previously inaccessible tissues
Other Considerations
Founded by Anders M. Näär, PhD, UC Berkeley Professor of Metabolic Biology; Based in Bakar Labs biotech incubator at UC Berkeley; Early-stage clinical data in non-human primates and pigs; Employee count of 2-10; Founded in 2021
See something that needs updating? Suggest edits to this profile.